6. Pharmacology of movement disorders Flashcards

1
Q

What is Parkinson’s disease?

A

Progressive disease of the NS associated with degeneration of the basal ganglia and a deficiency in dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How can PD be recognised histologically?

A

Loss of dopaminergic cells in the substantia nigra pars compacta
Presence of Lewy bodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are Lewy bodies?

A

Intracellular aggregations of protein alpha-synuclein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the relevance for the basal ganglia of reduced cells in the SNpC?

A

There will be reduced dopaminergic transmission to the caudate and putamen nuclei

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the common signs and symptoms of PD?

A
Motor:
Rigidity 
Tremor
Bradykinesia (three hallmarks of PD)
Also slow gait
Non-motor:
Dementia
Depression
Anxiety
Sleep disturbances
Olfactory dysfunction - loss of sense of smell
Constipation 
Microphagia - gradual development
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the pathophysiology of PD?

A

The substantia nigra pars compacta releases dopamine to the striatum (caudate + putamen)
The dopamine receptor for the direct pathway is D1 and the dopamine is excitatory to this receptor
The dopamine receptor for the indirect pathway is D2 and the dopamine is inhibitory to this receptor
SO the SNpc is tonically activating the direct pathway when movement is required

In PD, there is degeneration of the dopaminergic neurones in the SNpc
The excitatory input to the D1 receptors decreases (direct) and the inhibitory input to the D2 receptors (indirect) increases
SO the indirect pathway is facilitated and becomes dominant
There is an inhibition of the thalamus and this results in a decreased level of activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the prognosis of PD?

A

This is a progressive disease - motor symptoms will advance aggressively if not treated
The length of the disease is variable - patients typically lose independence after an average of 8 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is MTPT and what is it’s effect on PD?

A

MTPT is methyl-phenyl-tetrahydropyridine
This is transformed into metabolite MPP+ which is neurotoxic to dopaminergic neurones due to increased oxidative stress
This can result in the development of very toxic PD
This may be present in several illicit drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the problem with the oxidisation of dopamine and how does this occur?

A

Dopamine is oxidised by MAO (monoamine oxidases)
Dopamine is highly oxidisable by these MAOs and this metabolism results in the production of free radicals which can be damaging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the different treatment options for PD?

A
Dopaminergic compounds e.g. L-dopa
MAOb inhibitors
Anticholinergic (antimuscarinic) compounds
Amantadine 
COMT inhibitors 
Surgical grafts
Deep brain stimulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the mechanism of action of L-dopa?

A

Natural precursor of dopamine via DOPA decarboxylase

Formed from L-tyrosine via tyrosine hydroxylase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the adverse effects of L-dopa?

A
Nausea/vomiting
Postural hypotension
Psychosis
Impulse-control disorders
Excessive day-time sleepiness
Motor complications:
“On-off” effect - start to feel better as soon as you take a dose and then feel worse as your next dosage is due 
“Wearing-off”
 Dyskinesia
Dystonia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the advantage of selegeline?

A

Reduces oxidation of dopamine so this allows a lower dose of L-dopa to be administered - reduces the motor complications of L-dopa that are experienced by the patient

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the advantage of rotiglotin?

A

Administered as a transdermal patch with a slow release over 24 hours - this means that patients do not suffer the ‘on-off’ effect associated with L-dopa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the one problem with prescribing ritoglitone for PD?

A

Not effective in advanced PD - this is problematic when there is disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the cause for Huntington’s chorea/disease?

A

Autosomal dominant disease - changes in gene on chromosome 14
Abnormal number of repeats of glutamine (CAG codon) in the protein sequence
Results in a gain of function - accumulation of aggregates of the mutant Huntington protein

17
Q

What is meant by ‘chorea’?

A

Involuntary jerky movements

18
Q

What is the main problem with using L-dopa as a treatment for PD?

A

You will have an increased production of dopamine BUT this will go to all of the dopaminergic pathways in the brain - no way to specify
Excess dopamine in some pathways = adverse effects

19
Q

What are the dopaminergic pathways in the CNS?

A

Mesocortical pathway
Nigrostriatal pathway
Mesolimbic pathway

20
Q

Which is the CNS dopaminergic pathway that you want to increase dopamine in in the treatment of PD?

A

Nigrostriatal pathway - from the SNpC to the caudate and the putamen

21
Q

Why would you prescribe an anticholinergic in the treatment of PD?

A

A loss of dopamine results in hyperactivity of cholinergic cells - want to prevent this

22
Q

Why would you prescribe MAOb inhibitors in the treatment of PD?

A

To protect against dopamine oxidation via MAOb

23
Q

What is the role of amantadine in the treatment of PD?

A

Amantadine - inhibits dopamine reuptake and increases dopamine release

24
Q

How can you optimise the effect of L-dopa in the treatment of PD?

A

Mix with a COMT inhibitor e.g. entacapone

25
Q

What are the pathological changes in Huntington’s disease?

A

Cortical atrophy
Prominent striatal degeneration
Loss of medium spiny neurones
Intranuclear inclusions (vesicles)